Finance Watch: BioMarin Cuts 225 Jobs In Line With Recent Reorganization

Genentech Eliminates 93 Positions In California

Restructuring Edition: BioMarin’s layoffs are associated with strategic shifts announced during its second quarter update. Also, Repare reduced its workforce by 25% as it focused in on clinical-stage programs and Aadi cut 80% of its R&D team to conserve cash after a clinical trial failure.

Finance Watch Image — • Source: Shutterstock

BioMarin Pharmaceutical Inc. followed up its recent announcement of a shift in research and development priorities and a new commercial strategy for its hemophilia A gene therapy Roctavian (valoctocogene roxaparvovec) with a disclosure on 28 August that the company will reduce its global workforce by 225 people in line with its reorganization plans.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

23 Apr 2025

• By Sushmita Panda

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.

Europe Pharma Heavyweights Call For Higher Drug Prices At Home

23 Apr 2025

• By Kevin Grogan

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

22 Apr 2025

• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.